Baseline clinical and laboratory characteristics
| . | Patients (n = 16) . | Controls (n = 16) . |
|---|---|---|
| Age | 60 [48-65] | 49 [42-58]* |
| Female | 6 (38) | 7 (44) |
| Etiology of liver disease | ||
| Cholestatic liver disease | 4 | |
| Nonalcoholic steatohepatitis | 2 | |
| Alcoholic steatohepatitis | 4 | |
| Autoimmune hepatitis | 2 | |
| Hepatitis C virus | 1 | |
| Hemochromatosis | 1 | |
| Overlap syndromes | 2 | |
| BMI, kg/m2 | 28.7 [5] | 26.4 [4.4] |
| Diabetes | 4 (25) | 1 (6) |
| CVD | 5 (31) | 2 (13) |
| CTP A | 15 (94) | — |
| CTP B | 1 (6) | — |
| Ascites | 2 (13) | — |
| Encephalopathy | 0 | — |
| APTT, s | 34.4 [4.2] | 32.2 [2.7] |
| PT, s | 12.3 [2.4] | 11.0 [0.7]* |
| INR | 1.1 [0.2] | 1.0 [0.1]* |
| Fibrinogen, g/L | 2.8 [0.9] | 3.1 [0.7] |
| Prothrombin, % | 65 [15] | 102 [11]* |
| D-dimer, ng/mL | 517 [308-1049] | 185 [124-276]* |
| . | Patients (n = 16) . | Controls (n = 16) . |
|---|---|---|
| Age | 60 [48-65] | 49 [42-58]* |
| Female | 6 (38) | 7 (44) |
| Etiology of liver disease | ||
| Cholestatic liver disease | 4 | |
| Nonalcoholic steatohepatitis | 2 | |
| Alcoholic steatohepatitis | 4 | |
| Autoimmune hepatitis | 2 | |
| Hepatitis C virus | 1 | |
| Hemochromatosis | 1 | |
| Overlap syndromes | 2 | |
| BMI, kg/m2 | 28.7 [5] | 26.4 [4.4] |
| Diabetes | 4 (25) | 1 (6) |
| CVD | 5 (31) | 2 (13) |
| CTP A | 15 (94) | — |
| CTP B | 1 (6) | — |
| Ascites | 2 (13) | — |
| Encephalopathy | 0 | — |
| APTT, s | 34.4 [4.2] | 32.2 [2.7] |
| PT, s | 12.3 [2.4] | 11.0 [0.7]* |
| INR | 1.1 [0.2] | 1.0 [0.1]* |
| Fibrinogen, g/L | 2.8 [0.9] | 3.1 [0.7] |
| Prothrombin, % | 65 [15] | 102 [11]* |
| D-dimer, ng/mL | 517 [308-1049] | 185 [124-276]* |
Data are expressed as number (%), mean [SD], or median [IQR].
APTT, activated partial thromboplastin time; BMI, body mass index; CVD, cardiovascular disease; CTP, Child Turcotte Pugh; INR, international normalized ratio; PT, prothrombin time.
P < .05.